Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)

ClinicalTrials.gov ID: NCT01399918

Public ClinicalTrials.gov record NCT01399918. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 12:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Trial of Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to find out what effects, good and/or bad the combination of two medications, everolimus and bevacizumab, has on kidney cancer. In this clinical trial we are now testing these medications in combination. We think that both together might work better that either drug alone. Importantly, both of these drugs together have been tested in patients with a different type of kidney cancer and patients tolerated the combination well.

Study identification

NCT ID
NCT01399918
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Enrollment
57 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2011
Primary completion
Dec 27, 2020
Completion
Dec 27, 2020
Last update posted
Jan 31, 2022

2011 – 2020

United States locations

U.S. sites
7
U.S. states
2
U.S. cities
6
Facility City State ZIP Site status
Memorial Sloan Kettering at Basking Ridge Basking Ridge New Jersey 07920
Memorial Sloan Kettering Cancer Center at Basking Ridge Basking Ridge New Jersey 07939
Memorial Sloan Kettering Monmouth Middletown New Jersey 07748
Memorial Sloan Kettering Cancer Center @ Suffolk Commack New York 11725
Memorial Sloan Kettering Westchester Harrison New York 10604
Memorial Sloan Kettering Cancer Center New York New York 10065
Memorial Sloan Kettering at Mercy Medical Center Rockville Centre New York

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01399918, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 31, 2022 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01399918 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →